Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19307340 | READY-TO-USE ORAL LIQUID FORMULATION OF CLONIDINE | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19204307 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19196471 | RAS INHIBITORS | May 2025 | June 2025 | Allow | 1 | 0 | 0 | No | No |
| 19196483 | RAS INHIBITORS | May 2025 | March 2026 | Abandon | 10 | 1 | 0 | No | No |
| 19170770 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | April 2025 | February 2026 | Allow | 10 | 1 | 0 | No | No |
| 19070930 | RAS INHIBITORS | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19068133 | RAS INHIBITORS | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19062331 | RAS INHIBITORS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19053277 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | February 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19042105 | COMPOSITIONS AND METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS | January 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 18916325 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | October 2024 | October 2025 | Abandon | 12 | 2 | 0 | No | No |
| 18909401 | METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY | October 2024 | June 2025 | Allow | 8 | 2 | 0 | No | No |
| 18895095 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | September 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18790708 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18784243 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | July 2024 | April 2025 | Allow | 8 | 2 | 0 | No | No |
| 18652721 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS | May 2024 | February 2025 | Allow | 9 | 0 | 1 | No | No |
| 18603816 | OXYSTEROLS AND METHODS OF USE THEREOF | March 2024 | December 2024 | Allow | 9 | 1 | 0 | No | No |
| 18425761 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18573439 | APPLICATION OF CB-839 IN PREPARATION OF DRUG FOR INHIBITING CORNEAL NEOVASCULARIZATION (CNV) | December 2023 | July 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18445710 | Composition containing omega-3 for brain and heart health, and glucose metabolism | December 2023 | April 2025 | Abandon | 16 | 2 | 0 | Yes | No |
| 18390228 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18390195 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18518292 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18387180 | DRUG COMBINATION AND USE FOR TREATING TUMORS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18386337 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18371935 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18280132 | PREPARATION METHOD AND APPLICATION OF NOVEL INJECTION ABIRATERONE DERIVATIVE | September 2023 | November 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18454922 | COMBINED USE OF IN10018 AND PLD | August 2023 | August 2024 | Allow | 12 | 3 | 0 | Yes | No |
| 18262840 | THERAPEUTIC AGENT FOR HYPERTROPHIC CARDIOMYOPATHY | July 2023 | November 2025 | Allow | 28 | 0 | 0 | No | No |
| 18343182 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | June 2023 | March 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18215547 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | June 2023 | June 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18342312 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | June 2023 | May 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18332373 | Use of Malic Enzyme 1 (ME1) in Preparation of Drug for Preventing and Treating Pulmonary Hypertension (PH) | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18320264 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18143001 | TREATMENT OF ALZHEIMER'S DISEASE | May 2023 | November 2025 | Allow | 31 | 1 | 0 | No | No |
| 18139917 | Treatment of the adverse cardiovascular effects of cannabinoids | April 2023 | November 2025 | Allow | 30 | 0 | 0 | No | No |
| 18033621 | TETRAHYDRONAPHTHALENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | April 2023 | August 2025 | Allow | 28 | 0 | 0 | No | No |
| 18032895 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18133189 | PHARMACOKINETICS OF NMDA RECEPTOR ANTAGONISTS | April 2023 | June 2025 | Abandon | 26 | 4 | 0 | No | No |
| 18133201 | REDUCED SEDATION AND DISSOCIATION IN TREATING NEUROLOGICAL DISORDERS | April 2023 | June 2025 | Abandon | 26 | 4 | 0 | No | No |
| 18132919 | Combination treatment of dilated cardiomyopathy | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18131570 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | April 2023 | January 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18030405 | TREATMENT OF BIPOLAR DISORDERS AND PSYCHOSIS USING DEXMEDETOMIDINE HYDROCHLORIDE | April 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18130246 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | April 2023 | December 2025 | Allow | 32 | 2 | 1 | No | No |
| 18194038 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | March 2023 | March 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18027990 | TETRAHYDRO-SPIROINDOLINE-PYRROLOPYRROLE-TRIONES INHIBITORS OF THE NRF2-BETA-TRCP INTERACTION FOR USE IN THE TREATMENT OF FATTY LIVER DISEASE | March 2023 | November 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18188689 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | March 2023 | April 2024 | Abandon | 13 | 2 | 0 | No | No |
| 18188966 | RAS INHIBITORS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18027752 | METHOD OF TREATING GABA MEDIATED DISORDERS | March 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18245976 | THIONOESTER-DERIVATIVE OF RABEXIMOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18159232 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | January 2023 | January 2024 | Allow | 11 | 3 | 0 | Yes | No |
| 18152255 | Dosage Regimen for the Treatment of Cancer | January 2023 | March 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18147856 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | December 2022 | April 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18067387 | ORGANIC COMPOUNDS | December 2022 | November 2024 | Allow | 23 | 1 | 0 | No | No |
| 18066739 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | December 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 18063261 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | December 2022 | February 2024 | Allow | 14 | 3 | 0 | No | No |
| 18077966 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | December 2022 | March 2023 | Allow | 4 | 0 | 0 | No | No |
| 18062236 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | December 2022 | September 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17993616 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | November 2022 | December 2025 | Allow | 36 | 2 | 0 | No | No |
| 18057918 | MATERIALS AND METHODS FOR IMPROVING LUNG FUNCTION AND FOR PREVENTION AND/OR TREATMENT OF RADIATION-INDUCED LUNG COMPLICATIONS | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 18056848 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | November 2022 | September 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17926273 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | November 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 17997974 | ANTIDEPRESSANT/ANXIOLYTIC DRUG IN WHICH PAC1 RECEPTOR ANTAGONIST IS USED | November 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 17922892 | CYCLOSERINE AND PENTOXIFYLLINE COMBINATION THERAPY FOR TREATMENT OF DEPRESSION | November 2022 | May 2025 | Allow | 30 | 0 | 0 | No | No |
| 18047408 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | October 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17966646 | METHOD FOR OPTIMIZING 5-HYDROXYTRYPTAMINE FUNCTION IN THE BRAIN FOR THERAPEUTIC PURPOSES | October 2022 | May 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17918671 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | October 2022 | September 2025 | Allow | 35 | 1 | 0 | No | No |
| 17961765 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | October 2022 | May 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17938353 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | October 2022 | January 2023 | Allow | 3 | 1 | 0 | No | No |
| 17917285 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | October 2022 | January 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17917194 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | October 2022 | December 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17956139 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | November 2023 | Allow | 13 | 2 | 0 | Yes | No |
| 17949046 | Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus | September 2022 | July 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17943567 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | September 2022 | January 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17942657 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | September 2022 | December 2024 | Allow | 27 | 1 | 1 | No | No |
| 17823439 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17894809 | OPHTHALMIC COMPOSITIONS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17904554 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | August 2022 | October 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17904537 | Combinations for Treatment of NAFLD/NASH and Related Diseases | August 2022 | July 2025 | Allow | 35 | 1 | 0 | No | No |
| 17887962 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | August 2022 | May 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17929006 | FARNESOID X RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | August 2022 | November 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17882939 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17882695 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | August 2022 | June 2023 | Allow | 10 | 0 | 0 | No | No |
| 17817927 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | August 2022 | March 2024 | Allow | 20 | 1 | 0 | No | No |
| 17858889 | OPHTHALMIC COMPOSITIONS | July 2022 | December 2022 | Allow | 5 | 1 | 0 | No | No |
| 17850463 | COUMARIN DERIVATIVE FOR THERAPY OR PROPHYLAXIS OF A CELL PROLIFERATIVE DISORDER | June 2022 | April 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 17850322 | PHARMACEUTICAL FORMULATIONS OF IMATINIB AND USES THEREOF | June 2022 | May 2023 | Allow | 11 | 2 | 0 | No | No |
| 17757707 | COMPOSITION FOR TREATING SYNUCLEINOPATHIES | June 2022 | November 2025 | Allow | 41 | 2 | 0 | No | No |
| 17842632 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17841433 | OPHTHALMIC COMPOSITIONS | June 2022 | December 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17839169 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | June 2022 | December 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17837790 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2022 | October 2022 | Allow | 5 | 1 | 0 | No | No |
| 17833829 | CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION | June 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17782441 | METHODS FOR DRUG SCREENING AND COMPOSITIONS USEFUL FOR THE INHIBITION OF CELL PROLIFERATION AND/OR CELL SURVIVAL | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17780064 | METHODS OF TREATING PULMONARY ARTERIAL HYPERTENSION | May 2022 | July 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17825783 | COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIENTS | May 2022 | December 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17756503 | BENZOCOUMARIN AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17749583 | METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17662979 | METHOD OF TREATING LIVER FIBROSIS | May 2022 | November 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17736434 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VALENROD, YEVGENY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VALENROD, YEVGENY works in Art Unit 1628 and has examined 456 patent applications in our dataset. With an allowance rate of 82.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.
Examiner VALENROD, YEVGENY's allowance rate of 82.9% places them in the 56% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by VALENROD, YEVGENY receive 1.66 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by VALENROD, YEVGENY is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +15.8% benefit to allowance rate for applications examined by VALENROD, YEVGENY. This interview benefit is in the 56% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 34.5% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 43.5% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 85.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.9% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 81.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 37.5% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 16.0% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.